Entities / Company
Ipsen.
company in Barcelona, Spain
- Reports this week
- 0
- Active events
- 0
- Connections
- 34
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
Sanofi eliminated INOV investment value, while Ipsen and UCB acquired INOV portfolio companies.Some support1 report
-
A drug status update affecting Australian patients involves Ipsen and AstraZeneca, with changes made to the Pharmaceutical Benefits Scheme (PBS) on September 1, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Ipsen contributed royalties to Exelixis's collaboration revenues following the launch of CABOMETYX for NETs.Some support2 reports1 development inside
-
Albireo, Mirum Pharmaceuticals, and Ipsen are developing IBAT inhibitor therapies targeting conditions like MASH.Some support1 report
-
Ipsen received regulatory approval for Cabometyx, marking a competitive development with Merck in the renal cell carcinoma space.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Ipsen this week
News at the entities that move Ipsen mostConnections
The 3 strongest of 34, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Exelixis Operational
Ipsen and Exelixis maintain an operational partnership involving supply and collaboration revenue sharing.
-
Boulogne-Billancourt Structural
The company Ipsen maintains its headquarters in the municipality of Boulogne-Billancourt.
-
Europe Shared context
Ipsen operates and seeks regulatory approval within the European market.
History
Events by the month they beganSeptember 2026
2 eventsJune 2026
3 events- Ipsen contributed royalties to Exelixis's collaboration revenues following the launch of CABOMETYX for NETs.
- Albireo, Mirum Pharmaceuticals, and Ipsen are developing IBAT inhibitor therapies targeting conditions like MASH.
- Ipsen received regulatory approval for Cabometyx, marking a competitive development with Merck in the renal cell carcinoma space.